These include (1) vismodegib, a Hg inhibitor that targets a subset of CSCs in basal cell carcinoma[201] and other solid tumors, such as esophageal cancer[202]; (2) the BCL-2 inhibitor venetoclax, which selectively eradicates AML stem cells and demonstrated that 60% of patients receiving it with other chemotherapy drugs had complete clinical responses[202]; and (3) AT101, another pan-Bcl-2 inhibitor [Table 1], targets CSCs and is effective in esophageal and gastric cancer patients[203]. This evidence concerns the gene BCL2 and acute myeloid leukemia.